Zylo Therapeutics Inc.

Booth 3043
Greenville, South Carolina, United States
Zylö’s Z-pod™ topical delivery system--originally licensed from Albert Einstein College of Medicine--overcomes bioavailability challenges by providing: (i) improved stability; (ii) sustained release; (iii) targeting of the hair follicle unit (iv) reduced enzymatic degradation; and (v) the ability to provide sustained release of nitric oxide. Importantly, we also enable intellectual property claims around non-proprietary actives incorporated into our technology.